Uveal melanoma in HLA-A *02:01 positive patient

Uveal melanoma in an HLA-A\*02:01-positive patient refers to a primary intraocular malignancy arising from melanocytes within the uveal tract—comprising the choroid, ciliary body, or iris—in an individual expressing the human leukocyte antigen serotype allele HLA-A\*02:01 Pathophysiologically driven by oncogenic driver mutations in genes such as *GNAQ* or *GNA11*, this ocular cancer carries a high propensity for hematogenous dissemination, most commonly metastasizing to the liver

Uveal melanoma in an HLA-A\*02:01-positive patient refers to a primary intraocular malignancy arising from melanocytes within the uveal tract—comprising the choroid, ciliary body, or iris—in an individual expressing the human leukocyte antigen serotype allele HLA-A\*02:01 The presence of the HLA-A\*02:01 genotype serves as an essential immunogenetic biomarker, defining a distinct patient population capable of presenting specific tumor-associated antigens, such as glycoprotein 100 peptides, in an...

Uveal melanoma in an HLA-A\*02:01-positive patient refers to a primary intraocular malignancy arising from melanocytes within the uveal tract—comprising the choroid, ciliary body, or iris—in an individual expressing the human leukocyte antigen serotype allele HLA-A\*02:01 Pathophysiologically driven by oncogenic driver mutations in genes such as *GNAQ* or *GNA11*, this ocular cancer carries a high propensity for hematogenous dissemination, most commonly metastasizing to the liver

Pathophysiologically driven by oncogenic driver mutations in genes such as *GNAQ* or *GNA11*, this ocular cancer carries a high propensity for hematogenous dissemination, most commonly metastasizing to the liver

The presence of the HLA-A\*02:01 genotype serves as an essential immunogenetic biomarker, defining a distinct patient population capable of presenting specific tumor-associated antigens, such as glycoprotein 100 peptides, in an MHC class I-restricted manner

The presence of the HLA-A\*02:01 genotype serves as an essential immunogenetic biomarker, defining a distinct patient population capable of presenting specific tumor-associated antigens, such as glycoprotein 100 peptides, in an MHC class I-restricted manner

Clinically, affected patients often experience visual disturbances or painless vision loss, and in advanced or metastatic stages, this molecularly defined subset exhibits aggressive systemic progression requiring targeted immunotherapeutic management

Clinically, affected patients often experience visual disturbances or painless vision loss, and in advanced or metastatic stages, this molecularly defined subset exhibits aggressive systemic progression requiring targeted immunotherapeutic management